CTSO

#4457

Cytosorbents Corp.

0.60 USD

+1.69%

Сектор: Здравоохранение

Базовая: USD

Валюта прибыли: USD

Дневной диапазон

Годовой диапазон

Дневное изменение

+1.69%

Месячное изменение

-16.67%

6-месячное изменение

-34.78%

Годовое изменение

-42.31%

Предыдущее закрытие

0.59

Открыть

0.60

Bid

Ask

Минимум

0.60

High

0.60

Объем

Открыть полный график

Financials

Обзор Отчетность Статистика

Квартал Год

Market Capitalization 37.62 M
Employee 129
Founded 1997
CEO N/A
Website www.cytosorbents.com
Headquarter Delaware, United States
FIGI BBG000C3P8V0
Industry Technology

Общий доход

Чистая прибыль

Базовая прибыль на акцию

Общий долг

Свободный денежный поток

Денежные средства и эквиваленты

37.62 M Рыночная капитализация

Коэффициент цена/прибыль

-4.92

Коэффициент цена/денежный поток

1.07

Cytosorbents Corporation

CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey. CytoSorbents sells a cytokine adsorbing column — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood. The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns, which failed to show significance in a clinical trial for sepsis. The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy. Clinicaltrials.gov is giving an overview over running research projects. CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins.